GLP-1 vs GIP — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Glucagon-like peptide-1 (GLP-1 7-36 amide) is a 30-amino acid incretin hormone secreted postprandially by intestinal L-cells in response to nutrient ingestion, particularly fats and carbohydrates. GLP-1 is the parent molecule underlying the most important class of diabetes and ob...
Calculate GLP-1 dose →Glucose-dependent insulinotropic peptide (GIP) is a 42-amino acid incretin hormone secreted by K-cells of the small intestinal mucosa in response to nutrient ingestion. Along with GLP-1, GIP accounts for the incretin effect -- the amplification of glucose-stimulated insulin secre...
Calculate GIP dose →| Parameter | GLP-1 | GIP |
|---|---|---|
| Category | Incretin Hormone | Incretin Hormone |
| Research | Clinical | FDA Approved (via dual agonists) |
| Half-Life | 1.5-2 min (plasma, rapidly degraded by DPP-4) | ~7 min (plasma; degraded by DPP-4) |
| Typical Dose | 0.75-1.5 pmol/kg/min (IV research infusion) | Tirzepatide: 5-15 mg SC weekly |
| Frequency | Post-prandial release; IV for research | Weekly (tirzepatide) |
| Route | Intravenous (research); analogs SC/oral | Endogenous; SC (via dual agonist) |
| FDA Status | Not approved (analogs are FDA-approved) | Tirzepatide (dual GIP/GLP-1) FDA approved (Mounjaro, Zepbound) |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.